Navigation Links
Venaxis Executes First Commercial Development Agreement and Receives Purchase Order from EMELCA Bioscience for Initial EU Launch
Date:2/7/2013

CASTLE ROCK, Colo., Feb. 7, 2013 /PRNewswire/ -- Venaxis, Inc. (Nasdaq: APPY), an in vitro diagnostic company focused on obtaining FDA clearance and commercializing its blood-based appendicitis test, APPY1, today announced it has signed its first European commercial development agreement with Netherlands-based EMELCA Bioscience for the initial phase of Venaxis' EU launch.  Under the agreement, EMELCA will help Venaxis identify and engage with key opinion leaders and potential customers, as well as assess key market opportunities for APPY1 within the Benelux Territories, which includes Belgium, the Netherlands, and Luxembourg.  Pursuant to the agreement, Venaxis also received an initial stocking order from EMELCA, marking the first purchase order for APPY1.

During the initial launch phase, key market development activities will include working to identify and sign collaboration agreements with key opinion leader hospitals for the purpose of completing well-defined outcome studies over the coming months.  The studies are designed to further demonstrate the clinical utility and economic value of APPY1 in Europe and are expected to help Venaxis determine its precise marketing approach and advance in the second phase of the EU launch, a full-scale distribution and sales effort for APPY1, which is anticipated to advance and expand in 2013.

Don Hurd , Senior Vice President and Chief Commercial Officer of Venaxis, stated, "Our partnering with EMELCA Bioscience, a recognized leader in Europe, not only marks our first formal agreement Europe, it also represents the official launch of our market development efforts in the EU region where we have obtained CE Marking for APPY1.  EMELCA has considerable experience marketing and distributing diagnostic products in Europe and we are pleased by their commitment to Venaxis and to helping position APPY1 for success.  We look forward to finalizing agreements with other key enterprises for commercial development in other European territories, thereby laying the critical foundation that will allow us to facilitate a successful full-scale European product launch in 2013."

Patrick Van Der Meijden , Owner of EMELCA Bioscience, stated, "EMELCA is committed to understanding our customers' needs fully and to delivering the highest quality products and services.  The market development plan presented to us by Venaxis will lead to a more efficient and effective launch of APPY1.  For this reason, we are pleased to serve as Venaxis' partner and to begin offering APPY1 strategically to select customers during this initial launch phase."

About Venaxis, Inc.

Venaxis, Inc. is an in vitro diagnostic company focused on the clinical development and commercialization of its blood-based appendicitis test, APPY1.  The unique appendicitis test has projected high sensitivity and negative predictive value and is designed to aid in the identification of patients at low risk for acute appendicitis, allowing for more conservative patient management.  APPY1 is being developed initially for pediatric, adolescent and young adult patients with abdominal pain, as this population is at the highest risk for appendicitis and has the highest risk of long-term health effects associated with CT imaging.  For more information, visit www.venaxis.com.

Forward-Looking Statements

This press release includes "forward-looking statements" of Venaxis, Inc. ("Venaxis") (formerly AspenBio Pharma, Inc.) as defined by the Securities and Exchange Commission ("SEC"). All statements, other than statements of historical fact, included in this press release that address activities, events or developments that Venaxis believes or anticipates will or may occur in the future are forward-looking statements. These statements are based on certain assumptions made based on experience, expected future developments and other factors Venaxis believes are appropriate in the circumstances. Such statements are subject to a number of assumptions, risks and uncertainties, many of which are beyond the control of Venaxis. Investors are cautioned that any such statements are not guarantees of future performance. Actual results or developments may differ materially from those projected in the forward-looking statements as a result of many factors, including our ability to successfully complete required product development and modifications in a timely and cost effective manner, complete clinical trial activities for APPY1 required for FDA submission, obtain FDA clearance or approval, maintain CE Marking, cost effectively manufacture and generate revenues from APPY1, execute agreements required to successfully advance the company's objectives, retain the management team to advance the products, overcome adverse changes in market conditions and the regulatory environment, obtain and enforce intellectual property rights, and realize value of intangible assets. Furthermore, Venaxis does not intend (and is not obligated) to update publicly any forward-looking statements. The contents of this press release should be considered in conjunction with the risk factors contained in Venaxis' recent filings with the SEC, including its Form 10-Q for the period ended September 30, 2012, filed on November 7, 2012.

For Investors & Media:

Joshua Drumm , PhD / Jason Rando
Tiberend Strategic Advisors, Inc.
(212) 827-0020
jdrumm@tiberend.com 
jrando@tiberend.com

 

 

 


'/>"/>
SOURCE Venaxis, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Z Trim Holdings, Inc. Records First Non-GMO Corn Sales
2. ARAMARK Introduces Worlds First Reusable Validated Sterile Goggle That Remains Clear When Irradiated
3. First-to-Market Online Identity Theft Protection - Allweb Technologies Launches AllWebID
4. Origin Agritech Limited Reports Unaudited First Quarter Financial Results For Three Months Ended December 31, 2012
5. Patheon Announces First Phase of Additional Investment in Milton Park, UK Facility to Expand Early Development Capabilities in Europe
6. Pathway BioLogic is Chosen by Easy Gardener to Formulate the U.S.’s First Microbial Enhanced Natural Water Soluble Plant Food
7. First bedside DNA test to be introduced in Czech Republic
8. Waters Unveils Industrys First Integrated LC/MS Platform for Proteins, Peptides, and Glycans Analysis at WCBP 2013
9. Carolina Conceptions Announces the Delivery of their First Egg Freeze Pregnancy
10. CSL Behring enrolls first patient in global pediatric Phase III pivotal study of recombinant fusion protein linking coagulation factor IX with albumin (rIX-FP) to treat hemophilia B
11. First Point-of-Care DNA Test Submitted for FDA Clearance by Spartan Bioscience
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/30/2017)... , ... March 30, 2017 , ... ... a host of the Massachusetts Technology Leadership Council’s NewCo festival on April 5. ... leaders share their knowledge from the inside. , DrugDev – operating at ...
(Date:3/30/2017)... -- Personal Genome Diagnostics Inc. (PGDx) today announced that it ... Cancer Research (AACR) Annual Meeting 2017, being held April 1-5, ... also announced that five scientists associated with PGDx—two co-founders and ... AACR Team Science Award. ... Doug Ward , CEO of Personal ...
(Date:3/29/2017)... KING OF PRUSSIA, Pa. , March 29, 2017 ... access to care, which is why CSL Behring awards ... advocacy work of rare disease patient groups. These groups ... patients, voices are heard on Capitol Hill and in ... current funding cycle, the community-based grant was awarded to ...
(Date:3/29/2017)... , March 29, 2017 "Surging application ... deployed by the government are expected to drive the ... The gesture recognition market is expected to be ... CAGR of 29.63% between 2017 and 2022. The touchless ... billion by 2022, growing at a CAGR of 17.44% ...
Breaking Biology Technology:
(Date:3/24/2017)... Mar 24, 2017 Research and Markets has ... Market Analysis & Trends - Industry Forecast to 2025" report ... ... at a CAGR of around 15.1% over the next decade to ... report analyzes the market estimates and forecasts for all the given ...
(Date:3/22/2017)...   Neurotechnology , a provider of high-precision ... the release of the SentiVeillance 6.0 ... recognition using up to 10 surveillance, security and ... new version uses deep neural-network-based facial detection and ... a Graphing Processing Unit (GPU) for enhanced speed. ...
(Date:3/20/2017)... March 20, 2017 At this year,s CeBIT Chancellor ... biometrics manufacturer DERMALOG. The Chancellor came to the DERMALOG stand together with ... this year,s CeBIT partner country. At the largest German biometrics company the ... fingerprint, face and iris recognition as well as DERMALOG´s multi-biometrics system.   ... ...
Breaking Biology News(10 mins):